Clinical trial NCT03813173: Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma
Official title: Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma: a Prospective Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Lymph Node Metastases
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2019-01-23
Enrollment: 6000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is divided into three stages. In the first stage, the investigators try to explore the objective clinical imaging standard of cN0PTC on the basis of previous studies, formulate the "clinical imaging standard of cN0PTC", and randomly enroll 2000 patients under the premise of meeting the standard to establish the "predictive model of cN0-pN+PTC".

In the second stage, 2000 patients will be enrolled to test and improve the evaluation efficiency of "cN0-pN+PTC prediction model".

In the third stage, 2 000 patients without lymph node metastasis assessed by "cNo-pN+ PTC prediction model" will be randomly divided into experimental group and control group. The experimental group will be treated with pCND, while the experimental group will be treated without pCND. The central lymph node metastasis probability, the number and size of metastatic lymph nodes in the control group will be observed after operation. The two groups will be followed up for 5, 10, 15 and 20 years to observe the RFS and OS, so as to further evaluate the "cN0-pN+PTC prediction model" scientifically.


Eligibility criteria: Inclusion Criteria:

* Phase I and II:

  1. aged 18 to 80 years old;
  2. the primary treatment of patients with unilateral or bilateral PTC;
  3. ultrasound showed that the tumor was localized in the thyroid gland, and the maximum diameter of each lesion was less than 4cm;
  4. ultrasonography of cervical VI lymph nodes: the shortest diameter \< 4 mm, no calcification, no cystic change, no local or global echo enhancement;
  5. CT scan of cervical VI lymph nodes: the shortest diameter \< 4 mm, no calcification, no cystic change, no enhancement (CT value 40HU or not higher than banded muscle level), no cluster distribution;
  6. patients will voluntarily enter the study after informed consent;

Phase III:

1. aged from 18 to 80 years old;
2. ultrasound showed that the tumor was localized in the thyroid gland, and the maximum diameter of each lesion was less than 4cm;
3. Unilateral or bilateral PTC without lymph node metastasis assessed by "cNo-pN+ PTC prediction model";
4. patients will voluntarily enter the study after informed consent.

Exclusion Criteria:

* (1) patients refused to participate in the study; (2) non first operation patients; (3) Lateral cervical lymph nodes or distant metastasis; (4) Hashimoto's disease; (5) history of neck trauma.

Primary outcomes:
measure: Recurrence of thyroid cancer
timeFrame: Participants will be followed from the operation to 20 year (maximum)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: